Navigation Links
Study: MicroRNA cooperation mutes breast cancer oncogenes
Date:5/7/2013

A University of Colorado Cancer Center study recently published in the journal Cell Death & Disease shows that turning up a few microRNAs a little may offer as much anti-breast-cancer activity as turning up one microRNA a lot and without the unwanted side effects.

It's a bit like the classic thought experiment known as the "tumor problem" formulated by Karl Dunker in 1945 and used frequently in the problem-solving literature: Imagine a person suffers from a malignant tumor in the center of her body. Radiation strong enough to kill the tumor kills any healthy tissue through which it passes. Without operating or killing healthy tissue, how can a doctor use radiation to kill the tumor?

The answer is to target the tumor from many angles many weak rays of radiation pass harmlessly through healthy tissue, but their combined power at the point of the tumor is enough to kill it.

In the present study, CU Cancer Center investigators used "weak" induction of multiple microRNAs that combined from many angles to regulate the known breast cancer oncogenes erbB2/erbB3 (the "tumor") without regulating non-target genes (the "healthy tissue").

"Imagine you have a microRNA that regulates genes A and B. Then you have another microRNA that regulates genes B and C. You amplify each microRNA to a degree that doesn't effect gene A or C, but their combined effect regulates gene B," says Bolin Liu, MD, assistant professor in the Department of Pathology at the University of Colorado School of Medicine.

microRNA is an attractive target in cancer therapy more microRNA can lead to less gene expression, turning down or off the oncogenes that cause cancer. However, to get the desired effect on gene expression frequently requires enhancing microRNA expression 100- or 1,000-fold (or more). And the induced microRNA likely has other genetic targets it will turn down other genes as well as the oncogene, sometimes with unfortunate consequences
'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study: Environmental policies matter for growing megacities
2. Study: Widespread test-and-treat HIV policies could increase dangerous drug resistance
3. Study: Probiotics reduce stress-induced intestinal flare-ups
4. Study: Antibiotics are unique assassins
5. International study: Excess dietary salt may drive the development of autoimmune diseases
6. Influenza study: Meet virus new enemy
7. Study: Resveratrol shows promise to protect hearing, cognition
8. Nature Methods study: Using light to control cell clustering
9. Study: Viral reactivation a likely link between stress and heart disease
10. Study: Odd biochemistry yields lethal bacterial protein
11. International study: Where theres smoke or smog, theres climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... is available in German . During the ... humans, chromosomes are broken and rearranged at many positions. Using ... Klein, professor for genetics at the Max F. Perutz Laboratories ... high resolution. The surprising observations regarding the mechanism of meiosis ...
... part of human history for well over 30,000 years, used ... paint. Now, researchers from the Perelman School of Medicine ... have a new use for the 21st century: protecting healthy ... In a study just published in BMC Cancer , ...
... Total joint replacement surgeries can help relieve joint ... But sometimes, the debris from prosthetic joints leads ... In 2009, a Wayne State University researcher determined ... treat such disintegration. There was one caveat, however: ...
Cached Biology News:The machinery for recombination is part of the chromosome structure 2The machinery for recombination is part of the chromosome structure 3Penn study shows an ancient crop effective in protecting against a 21st century hazard 2Penn study shows an ancient crop effective in protecting against a 21st century hazard 3Wayne State researcher discovers antibiotic useful for localized treatment of bone wear 2
(Date:5/27/2015)... 27, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... immune therapies for cancer, announced today that Dr. ... Company, will be making an Industry Expert Theater Presentation ... Chicago on Saturday, May 30, 2015, from ... Theater in McCormick Place. Dr. Bosch will ...
(Date:5/27/2015)... May 27, 2015 The Medical Innovation ... impact of regulation on medical innovation, has been developed ... of Fairleigh Dickinson University’s ( FDU ) Rothman ... Alert pertains to new FDA (Food & Drug ... accelerating the approval of certain medical devices. , ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Innovacyn, ... solutions in the human and animal health industries, ... Vetericyn® Future Innovators of Agriculture College Scholarship Award. ... senior who exhibits a passionate commitment to the ... , This year’s winners, Alexis Pedrow from Anderson ...
(Date:5/26/2015)... 26, 2015  Alere Inc. (NYSE: ALR ) (the ... to timely file its Quarterly Report on Form 10-Q for ... it has received a notice from the New York Stock ... with the NYSE,s continued listing requirements under the timely filing ... Manual. The reason for the delay relates ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3
... Supply Chain Circassia to Develop Dopexamine as Part of ... ... OXFORD, England, October 8 Circassia Ltd, a specialty,biopharmaceutical ... today that it has acquired the US, Canadian and Japanese,development ...
... by allowing for the rapid ... of molecules using a single reaction, ST. LOUIS, ... that it has signed an exclusive licensing,agreement with the ... quantities of powerful new boronic acid,surrogates for use in ...
... for Landmark ApoA-I Trial, TSX Exchange Symbol: ... Corp.,("Resverlogix" or the "Company") (TSX:RVX) is pleased to ... RVX-208 Phase 2b clinical trial,assessing atherosclerosis by IVUS ... Syndrome patients expected to start in 2009., ...
Cached Biology Technology:Circassia Acquires North American and Japanese Rights to Dopexamine 2Circassia Acquires North American and Japanese Rights to Dopexamine 3Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 2Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 3International Steering Committee for RVX-208 IVUS Trial Formed 2International Steering Committee for RVX-208 IVUS Trial Formed 3
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
cysteine and glycine-rich protein 2,...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
Biology Products: